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Systems biology from virus to humans
Youri Lee1, Yu-Jin Kim1, Yu-Jin Jung1, Ki-Hye Kim1, Young-Man Kwon1, Seung Il Kim2 and Sang-Moo Kang1*
Abstract
Natural infection and then recovery are considered to be the most effective means for hosts to build protective
immunity. Thus, mimicking natural infection of pathogens, many live attenuated vaccines such as influenza virus,
and yellow fever vaccine 17D were developed and have been successfully used to induce protective immunity.
However, humans fail to generate long-term protective immunity to some pathogens after natural infection such as
influenza virus, respiratory syncytial virus (RSV), and human immunodeficiency virus (HIV) even if they survive initial
infections. Many vaccines are suboptimal since much mortality is still occurring, which is exampled by influenza and
tuberculosis. It is critically important to increase our understanding on protein components of pathogens and
vaccines as well as cellular and host responses to infections and vaccinations. Here, we highlight recent advances
in gene transcripts and protein analysis results in the systems biology to enhance our understanding of viral
pathogens, vaccines, and host cell responses.
Review
Introduction
Viruses contain all the essential factors necessary for
initiating infection and replication in a new target cell.
Thus, information on the protein composition of a virus
particle often serves as an initial guide in determining
functional roles for viral proteins as well as antiviral
and/or vaccine antigen target molecules. With advances
in proteomics techniques and the availability of anno-
tated genomic sequences for several mammalian species,
the view that a virion is a minimal package of its genome
and essential viral proteins for the first round of genome
replication is being changed. Proteomic analysis of vi-
rions identified host proteins that are packaged into the
virus particles along with the viral components (Table 1).
In particular, enveloped viruses have the capability to
incorporate numerous host proteins, both into the in-
terior of the virus particles as well as into the lipid en-
velope (Cantin et al. 2005; Bortz et al. 2003; Johannsen
et al. 2004; Kattenhorn et al. 2004; Zhu et al. 2005).
Similarly, host proteins have been detected in vaccinia
virions, human immunodeficiency virus (HIV) type 1, and
Moloney murine leukemia virus (MoMLV) vector par-
ticles (Chung et al. 2006; Chertova et al. 2006; Saphire
et al. 2006).
It is expected that cellular proteins found within the
virus particles would provide clues as to the virus assem-
bly pathway and events that govern virus infectivity as
well as vaccine development.
Vaccination is considered the most effective measure
to prevent global infectious diseases. Smallpox and polio
diseases are good successful cases of global threats that
almost disappeared by effective global vaccination. How-
ever, there are still many infectious diseases that claim
over 15 million deaths annually. Live attenuated influ-
enza virus (LAIV) vaccine was approved in 2003 and is
currently being used for human vaccination. LAIV is
safe and effective in young children and adults (Rhorer
et al. 2009). Recently, the use of noninfectious virus-
like particles (VLPs) that self-assemble by spontaneous
interactions of viral structural proteins has been sug-
gested and developed as alternative approaches for de-
veloping advanced vaccines for a wide range of viruses
that cause disease in humans (Roy and Noad 2009;
Kang et al. 2009a; Kang et al. 2009b). It is worth noting
that a VLP-based human papillomavirus (HPV) vaccine
against HPV responsible for cervical cancer was pro-
duced in the yeast system and approved for the market
in 2006 (Garland et al. 2007).
Influenza VLPs expressed by recombinant baculovirus
(rBV) systems that present multi-component antigens,
including HA and matrix 1 (M1), with or without NA,
and that are capable of inducing cognate responses against
homologous strains of influenza virus have been widely
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described (Roy and Noad 2009; Kang et al. 2009a; Kang
et al. 2009b). In particular, 2009 H1N1 new pandemic,
H5N1, and H7N9 avian influenza VLP vaccines were pro-
duced by the insect cell rBV expression system, and tested
in clinical trials, demonstrating their safety and efficacy
(Khurana et al. 2011; Lopez-Macias 2012; Lopez-Macias
et al. 2011; Klausberger et al. 2014; Smith et al. 2013; Fries
et al. 2013). Also, influenza VLPs were engineered to ex-
press highly conserved influenza virus M2 ectodomains
and found to induce cross immunity to heterologous in-
fluenza virus strains (Kim et al. 2013a; Kim et al. 2014;
Kim et al. 2013b).
Any cellular proteins that may be incorporated into
viral particles are also likely to be present at very low
levels. Mass spectrometry of tryptic peptides combined
with database searching for identification is now becom-
ing the preferred and advanced method for such prote-
omic studies revealing details on protein components
even at a very low level (Table 1).
Vaccinology and immunology were born from the pio-
neering work of scientists such as Jenner and Pasteur
over 200 years ago. Despite the common origins of vac-
cination and immunology concepts, the two disciplines
have evolved in parallel directions independently. Immu-
nologists remain largely ignorant about the mechanisms
of how vaccines work. Meanwhile, vaccines were made
empirically, and until recently, vaccinologists have shown
little interest in the immunological mechanisms by which
the vaccine confers protective immunity. Better unders-
tanding of immunological mechanisms of vaccination is
expected to provide informative insights into the rationale
design of future vaccines against difficult pathogens.
The innate immune system including dendritic cells
(DCs), macrophages, and other immune cells senses vi-
ruses, bacteria, parasites, and fungi through pathogen-
recognizing receptors (PRRs) (reviewed in (Coffman
et al. 2010; Kawai and Akira 2007; Iwasaki and Medzhitov
2010)). The nature of the DC subtypes and the particular
PRR triggered plays an essential role in modulating the
strength, quality, and memory of adaptive immune res-
ponses (Pulendran and Ahmed 2006; Steinman 2008).
More than 26,000 genes are estimated to be present in
human genomes. Exposure to a pathogen or vaccination
introduces changes in the expression of a substantial
fraction of these genes. Systems biological tools offer an
informative insight into the complex network of the
immune system in our body. That is, high-throughput
data on the genes, mRNAs, microRNAs, and proteins
that constitute the biological networks are providing
new information in our overall understanding of complex
immune systems. Systems biology capitalizes on several
‘omic’ technologies that might define and monitor all the
components of the systems. Thus, recent advances in the
innate immune system and the use of systems biological
approaches are providing powerful tools to reveal the
basic mechanisms by which the innate immune system
modulates protective immune responses to vaccination
(Pulendran and Ahmed 2006; Steinman 2008).
This review focuses on proteomic components of some
viruses and vaccines (Table 1), cellular responses of host
target cells and immune cells upon exposure to virus and
vaccines (Table 2), as well as in vivo gene expression pro-
files in animals and humans in response to respiratory
viral infection or certain successful vaccinations.
Table 1 Proteomic analysis of representative host cell proteins incorporated into virus or virus-like particles
Virus Host proteins in virus or VLP*
Influenza virusa ADAR3, H2A, HSP90, nucleolin, ITGAV, hnRNPA1, glypican 4 (kglypican), ANXA4, CD9, CD81, cofilin 1, cyclophilin A,
profilin, HSP27, integrin beta, ANXA11, CD59
Respiratory syncytial virusb
Cytoskeleton B-actin, keratin, moesin, filamin-A, TUBA1B, TUBB, HSP70, HSP90-alpha,beta
Energy pathways ALPI, PK, GAPDH
Immune response Putative annexin A2-like protein, ANXA1, CD55
H5N1 VLPc ADP-ribosylation factor, alpha tubulin, Arp2/3 complex subunit, beta-tubulin 10, actin, 40S ribosomal protein S24,
60S acidic ribosomal protein P1,2, ribosomal protein L40, HSP90, heterotrimeric G-protein gamma subunit-like protein,
putative Rho1, glutathione S-transferase sigma, ATPase subunit C, casein kinase II subunit alpha, fatty acid-binding
protein, 14-3-3 zeta, Rbp1-like RNA-binding protein PB
H5N1/H3N1 VLPd b-tubulin, Myosin, ECM proteins integrin alpha, HSP90, HSP70, HSP27, annexin, tetraspanin, CD9, glycolytic enzymes
enolase 1, pyruvate kinase, glyceraldehyde-3-phosphate dehydrogenase, unclassified proteins, aldo-keto reductase
family 1, WD repeat domain 1, gamma-glutamyltransferase, peroxiredoxin 2
aInfluenza virus (H1N1,A/Cal/07/2009) was purified after growing in A549 cells (Shaw et al. 2008; Dove et al. 2012).
bRespiratory syncytial virus was purified after growing in A549 cells (Radhakrishnan et al. 2010).
cH5N1 VLPs (H5N1, A/Indonesia/102 5/2005) were purified after expressing in SF9 insect cells (Song et al. 2011).
dH3N2/H5N1 VLPs (H3N2, A/Taiwan/083/2006 and H5N1, A/Hanoi/30408/2005H5N1) were purified after expressing in Vero cells (Wu et al. 2010).
*Adenosine deaminase, RNA-specific, 3 (ADAR3), histone 2A (H2A), heterogeneous nuclear ribonucleoprotein A1 (hnRNP1), tubulin alpha-1B (TUBA1B), tubulin B
(TUBB), intestinal type alkaline phosphatase (ALPI), heat shock protein 27 kDa (HSP27) peroxiredoxin (PRX), annexin A 4 (ANXA4), annexin A11 (ANXA11), annexin
A11 (ANXA1), integrin alpha V (ITGAV), dynein 1, heat shock protein 90 kDa (HSP90), heat shock protein 70 kDa (HSP70), pyruvate kinase (PK), beta-actin (B-actin),
alkaline phosphatase (ALPI), complement decay acceleration factor (CD55), glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
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Cellular and viral proteins within virus and virus-like
particles
Influenza virus
With advances in proteomic analysis and studies, a vir-
ion is not simply a package of its genome and viral pro-
teins. Numerous host cellular proteins were found to
be incorporated into virus particles in particular en-
veloped virions. HIV virions were found to incorporate
Tsg101, cyclophilin A, and APOBEC3G in addition to
their viral proteins (Chertova et al. 2006; Saphire et al.
2006; Demirov et al. 2002; Franke et al. 1994; Mariani
et al. 2003). Tsg101 host protein was reported to play a
crucial role in virus assembly of HIV whereas cyclophi-
lin A modulates HIV-1 infectivity and APOBEC3G is
an anti-viral factor that promotes hypermutation of the
viral genome (Franke et al. 1994; Mangeat et al. 2003).
Among many other cellular proteins, identification of
these three host proteins has increased our understanding
of how HIV would interact with its host proteins. Nine
viral proteins out of the 11 influenza A virus proteins are
present in the influenza virion (PB1, PB2, PA, HA, NP,
NA, M1, M2, NEP). The glycoproteins hemagglutinin
(HA) and neuraminidase (NA) are embedded into the
lipid envelope of the influenza virus particle and form the
spikes visible under the electron microscope. The ion
channel protein M2 is also found within the virion but
at a lower level. The matrix M1 protein lies beneath the
viral membrane, surrounding the ribonucleoproteins,
which consist of eight viral RNA segments coated with
the nucleoprotein (NP) and bound by the trimeric poly-
merase complex (PB1, PB2, PA). The nuclear export pro-
tein (NEP) is also found within influenza virus particles.
By utilizing mass spectrometry of tryptic peptides
(multidimensional protein identification technology liquid
Table 2 Representative gene expression profiles in host cells as a result of virus infection or VLP stimulation
Host cells Virus/VLPs Gene expression profiles in host cells*
MDCKa Influenza TUBA2, CK-8, B-actin, keratin 10, ANXA1, KCIP-1
VEROb Influenza Keratin1, 8, 10, tubulin, TUBA, RBBP4, ITGA3, HSP27, Ndr1, ANXA4, PK, GAPDH, HSP105, ITGAV, dynein 1,
HSP90, ITGA3, HSP 70
A549c RSV HRNR, HIST2H2BE, HIST1H2BC, H2AFX, DTX3L, IFI35, SYNE1, SUMO2, MYADM, PARP14, VIM, C21ORF70,
TFAM, POLDIP3, DEK, EFHD2, KIAA1967, ENO1, ENY2
BEAS-2BdHBEC RSV ATP6V0D2, OTOA, SCNN1G, SMA5, CYP4F8, EPB41L4B, ELP2, PRKCE, HBP1, DUSP2, TUBB1, TRNT1, ELOVL5,
PTPRG, MAP2K7, TSGA10, KRT12, SYN1, SIRPB1
MDDCe HIV-VLP Expression of genes involved in the morphological and functional changes characterizing the MDDCs
activation and maturation: MEF2A, NFE2L2, DC-UbP, PGM3, DGKH, PTGS2, IL8, ARRB1, BTG3, SOSTM1,
HLA-DOA - MHC class II, TADA3L, MTHFD2, PRKX, BAG3 KCNK10, member 10, PBEF1
PBMCf HIV-VLP Expression of genes involved in the morphological and functional changes characterizing the PBMCs
activation and maturation: CTSL, IL3RA, SMOX, BCL2, G0S2, IER3, SERPINB2, LIMK2, IL6, IL8, PBFE1, PBX3,
IL1-A,B, CCL3 (MIP 1α), CCL7, CCL18, CCL20, CXCL1, CXCL2, CXCL3, CXCL6, CXCL13, INHBA, ACTN1, AQP9,
EMR1, SLC25A37, SLCO4A1, MAD, CCL4 (MIP1β)
RAW264.7g HBc-VLP HSP70, Eno1 protein chain A, peroxiredoxin 1, phosphoglycerate kinase, glutathione S-transferase A2,
ferritin light chain 1, hypothetical protein, prohibitin, glyceraldehyde-3-phosphate dehydrogenase
aMadin-Darby canine kidney (MDCK) cells that were infected with influenza virus (H1N1, A/PR/8/34) (Vester et al. 2010).
bVero (kidney epithelial cells) cells that were infected with influenza virus (H1N1, A/PR/8/34) (Vester et al. 2010).
cA549 (adenocarcinomic human alveolar basal epithelial cells) cells were infected with respiratory syncytial virus (Munday et al. 2010).
dBEAS-2B4 (human bronchial epithelial cell line, subclone S6), human bronchial epithelial cells (HBEC) were infected with respiratory syncytial virus
(Huang et al. 2008).
eHuman monocyte-derived dendritic cells (MDDCs) were stimulated with HIV-1 (clade A) Pr55gag virus-like particles (HIV-VLPs) (Arico et al. 2005).
fCD14+ human peripheral blood mononuclear cells (PBMCs) were stimulated with HIV-1 Pr55gag virus-like particles (HIV-VLPs) (Buonaguro et al. 2008).
gRAW264.7 (mouse macrophage cell line) cells were stimulated with hepatitis B virus core protein virus-like particles (HBc-VLPs) (Yang et al. 2008).
*Influenza: H1N1 (A/PR/8/34), HIV-VLp (HIV-1 Pr55gag virus), HBc-VLP (hepatitis B virus). Tubulin alpha (TUBA), protein kinase C inhibitor protein-1 (KCIP-1),
nameretinoblastoma binding protein 4 (RBB4), serine/threonine kinase 38 (Ndr), MADS box transcription enhancer factor 2 (MEF2A), nuclear factor-like 2 (NFE2L2),
dendritic cell-derived ubiquitin-like protein (DC-UbP), phosphoglucomutase 3 (PGM3), diacylglycerol kinase (DGKH), prostaglandin-endoperoxidase synthase 2
(PTGS2), interleukin 8 (IL-8), arrestin beta 1 (ARRB1), BTG familymember 3 (BTG3), sequestosome 1 (SOSTM1), MHC class II (HLA-DOA), butyrate-induced transcript
(HSPC121), transcriptional adaptor 3 (TADA3L), Mst3 and SOK1-related kinase (MST4), UDP-Gal:betaGlcNAc bea 1.4-galactosyltransferase (B4GALT5),
NAD-dependent methylenetetrahydrofolate dehydrogenase (MTHFD2), small glutamine-rich tetratricopeptide repeat (SGTB), protein kinase (PRKX), Nedd4 binding
protein 1(X-linked N4BP1), pellino homologue 1(PELI1), sterol-C4-methyl oxidase-like (SC4MOL), BCL2-associated athanogene 3 (BAG3), potassium channel,
subfamily K (KCNK10), pre-B-cell colony enhancing factor 1 (PBEF1), hornerin (HRNR), H2B type 2-E (HIST2H2BE), H2B type 1-C/E/F/G/ (HIST1H2BC), H2A (H2AFX),
protein deltex-3-like (DTX3L), interferon-induced 35 kDa protein (IFI35), Nesprin-1 (SYNE1), small ubiquitin-related modifier 2 (SUMO2), myeloid-associated
differentiation marker (MYADM), poly [ADP-ribose] polymerase 14 (PARP14), vimentin (VIM), uncharacterized protein C21orf70 (C21ORF70), transcription factor A,
mitochondrial (TFAM), polymerase d-interacting protein 3 (POLDIP3), protein DEK (DEK), EF-hand domain-containing protein D2 (EFHD2), protein KIAA1967
(KIAA1967), a-enolase (ENO1), enhancer of yellow 2 transcriptionfactor homologue (ENY2), ATPase, H+ transporting, lysosomal 38 kDa, V0 subunit d isoform 2
(ATP6V0D2), otoancorin (OTOA), sodium channel non-voltage-gated 1 gamma (SCNN1G), cytochrome P450 family 4 subfamily F polypeptide 8 (CYP4F8),
erythrocyte membrane protein band 4.1 like 4B (EPB41L4B), signal transducer and activator of transcription 3 interacting protein 1(ELP2), protein kinase C epsilon
(PRKCE), HMG-box transcription factor 1 downregulated genes (HBP1), dual specificity phosphatase 2 (DUSP2), tubulin beta 1 (TUBB1), tRNA nucleotidyl transferase
CCA-adding 1 (TRNT1), ELOVL family member 5 elongation of long chain fatty acids (ELOVL5), protein tyrosine phosphatase receptor type G (PTPRG), mitogen-
activated protein kinase 7 (MAP2K7), testis specific 10 (TSGA10), keratin 12 ( KRT12), synapsin I (SYN1), signal-regulatory protein beta 1 (SIRPB1), glucuronidase,
beta pseudogene (SMA5), EGF-like module containing, mucin-like, hormone receptor-like sequence 1(EMR1).
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chromatography-tandem mass spectrometry (LC-MS/MS)
analysis) combined with database searching for identifica-
tion, 36 host-encoded proteins were identified in the influ-
enza A/WSN/33 (H1N1) virus particles that were grown
in Vero (African green monkey kidney) cells (Shaw et al.
2008). The following host cell proteins are also found in
other enveloped viruses. (i) Cytoskeletal proteins: Cyto-
skeletal proteins such as tubulin and actin were present
in the interior of influenza virions which most likely
reflects their active participation in moving the viral
components to the assembly site and possible cytoske-
letal reorganization that occurs during bud formation.
(ii) Annexins: Several annexin family members (A1, A2,
A4, A5, and A11) were found in influenza virus par-
ticles. Annexins are calcium-dependent phospholipid-
binding proteins and are proposed to act as scaffolding
proteins at certain membrane domains. (iii) Tetraspanins:
Two members of the tetraspanin family, CD9 and CD81,
were present within influenza virions and are most likely
inserted into the viral envelope. Tetraspanins have four
transmembrane domains and two extracellular loops and
are involved in specialized membrane domains. Tetraspa-
nins (CD9 and CD81) have also been implicated in both
fusion and egress pathways for a number of other viruses
(Ho et al. 2006; Jolly and Sattentau 2007). (iv) Cyclophilin
A: Cyclophilin A (a peptidyl-prolyl isomerase) was shown
to be in the core of the influenza virion and in other dif-
ferent viruses. There is a precedent for the involvement of
cyclophilin proteins in replication of different viruses. (v)
CD59: CD59 is a complement regulatory protein that acts
by inhibiting formation of the membrane attack complex.
CD59 (glycosylphosphatidylinositol membrane anchored
protein) was found to be associated the influenza virus en-
velope. Enveloped viruses are susceptible to direct
complement-mediated lysis and incorporating CD59 (with
DAF and CD46) into lipid envelope is considered to play a
protective role from membrane attack by the host comple-
ment system. This has important implications for virus
host-range. The virus produced and transmitted within
the same host species would be protected since comple-
ment control proteins are highly species specific. However,
virus transmitted to another host species would become
susceptible to lysis by the complement system from a dif-
ferent host. (vi) Metabolic enzymes: Proteomic analysis of
influenza virus particles identified a number of proteins
involved in the glycolytic pathway (pyruvate kinase, eno-
lase 1, GAPDH glyceraldehyde-3-phosphate dehydrogen-
ase, phosphoglycerate kinase). It is possible that some of
these cellular proteins might have other additional func-
tions such as viral RNA genome transcription.
Respiratory syncytial virus
Respiratory syncytial virus (RSV) is the most important
respiratory virus causing lower respiratory tract infection
in young children and neonates. There is no vaccine
against RSV. In contrast to influenza virus, formalin
inactivated RSV (FI-RSV) in alum adjuvant formulation
is known to cause vaccine-enhanced respiratory disease
(Kapikian et al. 1969; Kim et al. 1969). Reinfections are
common throughout life, indicating that natural RSV
infection fails to establish long-lasting immunity (Hall
et al. 1991; Piedra 2003; Bont et al. 2002; Nokes et al.
2008; Scott et al. 2006; Glezen et al. 1986). Identification
of protein components of RSV might provide a unique
clue to therapeutic intervention or vaccine design targets.
The RSV A2 strain was produced in the human res-
piratory airway cell-line Hep2 and purified using su-
crose gradient ultracentrifugation. The RSV protein
components were analyzed by one-dimensional nano-
LC-MS/MS, resulting in identification of 26 cellular
proteins in addition to all the major virus structural
proteins (Radhakrishnan et al. 2010). Representative
host cell proteins associated with purified RSV parti-
cles include proteins associated with the cortical actin
network, energy pathways, and heat shock proteins
(HSP70, HSC70, and HSP90). In particular, the HSP90
protein was suggested to play an important role in the
RSV assembly process. The presence of virus-associated
actin network proteins as well as cofilin-1, caveolin-1, and
filamin-1 in the mature virus may indicate an important
role in RSV assembly in lipid raft microdomains and in
maintaining the RSV architecture. Unlike other viruses,
high levels of heat-shock proteins associated with RSV
particles remain unclear for their significance.
Protein components of VLPs as vaccine candidates
Influenza VLP vaccines that were produced using the
rBV-insect cell expression system were demonstrated to
be safe and immunogenic in the clinical trials of healthy
adults (Khurana et al. 2011; Lopez-Macias et al. 2011).
Insect cell culture derived influenza VLP vaccines were
shown to be more immunogenic compared to the con-
ventional egg-substrate split vaccines (a Phase II human
clinical trial of the trivalent seasonal influenza VLP vac-
cine candidate, Novavax, Inc.). These clinical studies
demonstrated the safety and efficacy of VLP vaccines
produced in insect cells using the rBV expression sys-
tem. Thus, it is highly significant to have information on
protein components of VLP vaccines. Using one-DE-LC-
MS/MS technology, comprehensive proteomic analysis
of the insect cell derived, rBV expressed influenza H5
VLPs identified viral proteins as vaccine target antigens
as well as 37 additional host-derived proteins (Song et al.
2011). Many of host-cell-derived proteins in influenza
VLPs are known to be present in other enveloped viruses
and involved in different cellular structures and func-
tions including those from the cytoskeleton, translation,
chaperone, and metabolism. Influenza H5 VLPs produced
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in insect cells were found to be associated with host
proteins involved in actin cytoskeleton, vesicular traf-
ficking (ADP-ribosylation factor, vesicle-associated mem-
brane proteins, vacuolar protein sorting 28, myosin II
essential light chain), heat-shock protein 90, ribosomal
proteins, putative ubiquitin/ ribosomal protein S27Ae
fusion protein, and cell-signaling-related proteins (het-
erotrimeric guanine nucleotide binding protein gamma
subunit-like protein, Rho1). As expected, many rBV vector-
derived proteins were also found to be in H5 VLPs. These
structural proteins originated from rBV include occlu-
sion derived and polyhedron associated proteins (AcOrf-
102, −114), capsid or capsid associated proteins, and
baculovirus envelope proteins.
Mammalian influenza VLPs may more closely mimic
authentic virions in their morphology, in functional HA,
and in other molecular constituents. Stably transformed
Vero cells expressing influenza M1, M2, HA, and NA
were used to produce mammalian influenza H3N2 VLPs
and H5N1 VLPs (Song et al. 2011). Proteomic analysis
of mammalian VLPs using LC-MS/MS technologies
identified 22 VLP-associated cellular proteins that are
analogous to those cellular proteins commonly found in
the influenza virions (Song et al. 2011). These cellular
proteins incorporated into mammalian influenza VLPs
include cytoskeleton proteins, extracellular matrix pro-
teins, heat shock proteins, annexins, tetraspanins, clathrin
heavy chain, and glycolytic enzymes. Thus, the cellular
proteins identified in VLPs without viral genomes are im-
portant in the normal virus life cycle during virus assem-
bly and budding from the host cells.
Host cell gene expression profiles upon viral infections or
in response to VLPs
A proteomic approach applying the quantitative 2-D
DIGE and nanoHPLC-nanoESI-MS/MS analysis was used
to investigate the dynamic cellular host cell response in-
duced by influenza virus infection in two different cell
lines, Madin-Darby canine kidney (MDCK) and Vero
cells. Upon influenza virus (A/PR/8/34) infection, changes
in gene expression of MDCK infected cells were observed
in the interferon (IFN)-induced signal transduction, cyto-
skeleton remodeling, vesicle transport, and proteolysis
(Vester et al. 2010). In Vero cells infected with influenza
virus, alterations of gene expression include heat shock
and oxidative stress response-related proteins.
To gain an understanding of the RSV associated host
cell gene expression, differentially expressed genes in hu-
man respiratory epithelial cells (A549) were determined
by cDNA microarray analysis after RSV infection (Martinez
et al. 2007). Among 85 genes that were up-regulated at
early times post infection (0 to 6 h post infection (pi)),
most highly expressed genes are involved in chemotaxis,
inflammation, and some integrins. Genes related to IFN-
stimulation and NF-ƙB pathways were up-regulated be-
tween 6 and 12 h pi. At later times post infection, immune
response-related genes were expressed at high levels.
These findings suggest a temporal relationship between
RSV infection and the host response to RSV replication.
Supplementary validation experiments using conventional
methods are required to confirm these findings.
HIV-1 gag virus-like particles (HIV-VLPs) produced
by the recombinant baculovirus expression system was
used to stimulate CD14+ monocyte-derived dendritic cells
(MDDCs) enriched from peripheral blood mononuclear
cells (PBMCs) of normal healthy donors (Buonaguro et al.
2008). Genomic transcriptional profile of HIV-VLPs acti-
vated MDDCs revealed high expression of genes that are
responsible for activation and maturation of MDDCs.
Representative genes up-regulated include antigen pro-
cessing and presentation (IL3RA, BCL2), cell shape and
extracellular matrix, chemokine and cytokines (IL-6), cy-
tokine network (IL1A, B), cytokine-receptor interactions,
immune response membrane proteins, chemokine recep-
tors (CCL3, 4), and Toll-like receptor (TLR) signaling
pathway (IL8). Similar data of gene expression profile were
also reported to be observed using PBMCs activated by
HIV-VLPs (Buonaguro et al. 2008). The same group of
study demonstrated that the effects of HIV-VLPs on
MDDCs are not mediated through TLR2 and TLR4 sig-
naling (Buonaguro et al. 2006). Also, influenza VLP-
loaded MDDCs that were obtained from human healthy
donors were demonstrated to be effective in generating
functional CD8 T cells (Song et al. 2010), implicating
that VLP vaccines can induce both humoral and cellu-
lar host immune responses.
Hepatitis B virus core antigen VLP (HBc-VLP)-pulsed
and control macrophage cells (RAW264.7) were sub-
jected to two-dimensional electrophoresis and tandem
MS (Yang et al. 2008). Analysis of differentially expressed
proteins revealed that heat-shock protein 70 and prohibi-
tin in addition to proteins in the glycolytic pathway were
highly up-regulated upon stimulation with HBc-VLPs. It is
speculated that stress-response proteins (HSP70, prohibi-
tin) may contribute to the uptake, processing, and presen-
tation of VLP vaccine particles.
Animal models and systems biology to better understand
pathogenesis and vaccination
The dynamics of virus pathogenesis are multifaceted and
can be better comprehended by looking at the system as
a whole. Human patients with highly pathogenic avian
influenza H5N1 virus typically develop a viral primary
pneumonia progressing rapidly to acute respiratory dis-
tress syndrome (Abdel-Ghafar et al. 2008). An aberrant
immune response is thought to play a significant role in
the severe respiratory disease that may ultimately lead
to death (Peiris et al. 2009). The term ‘cytokine storm’
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referring to an uncontrolled inflammatory response is
often associated with H5N1 virus pathogenesis (Tisoncik
et al. 2012). Human patients infected with H5N1 virus
were shown to have high serum levels of pro- and anti-
inflammatory cytokines (IL-6, IL-10, IFN-γ), macrophage
and neutrophil chemoattractant chemokines (CxCL10,
CXCL2, IL-8) (de Jong et al. 2006; Peiris et al. 2004; To
et al. 2001). Host response to influenza H5N1 virus has
been investigated in non-human primate, mouse, and fer-
ret models. Global transcriptional profiling of infected
lungs has revealed that virulence of influenza virus is as-
sociated with increased early and sustained inflammatory
responses. Genes that showed correlates with disease se-
verity during H5N1 virus infection include inflammasome
components, viral sensing, neutrophil activation, NF-κB
signaling, and chemokine signaling (Ibricevic et al. 2006;
Cilloniz et al. 2010; Baskin et al. 2009; Cameron et al.
2008; Chang et al. 2011; Shinya et al. 2012).
It is suggested that lung homeostasis is lost when the
innate immune system reached a high level of activation
but was unable to contain the pathogen before viral
cytopathicity (Boon et al. 2011; Sanders et al. 2011). The
depletion of innate immune cell types lowered inflam-
matory cytokine levels in mouse lung homogenates but
resulted in elevated lung viral titers, systemic virus
spread, and reduced survival (Tumpey et al. 2005). Mice
with decreased myeloid infiltrates and lack of NLRP3
inflammasome activation exhibited high susceptibility
to influenza infection (Allen et al. 2009; Thomas et al.
2009). Selective neutrophil targeting in infected mice
caused enhanced mortality (Tate et al. 2009). Therefore,
innate inflammatory cells have host-beneficial functions
rather than a primary causal role in pathology (Brincks
et al. 2008; Tate et al. 2012).
An alternative view is that lung function is largely dys-
regulated through the damaging effects of leukocytes on
epithelial and endothelial cells (Aldridge et al. 2009; Le
Goffic et al. 2006; Lin et al. 2008). In support for this
idea, monocyte-derived inflammatory macrophages and
dendritic cells contributed to fatality (Lin et al. 2008).
The relative pathogenic contributions of direct viral cy-
topathic damage versus dysregulated host inflammatory
responses to lethal influenza infections remain as an
important question to be answered. By using extensive
microarray analysis of multigene transcriptional signatures
from infected mouse lungs, a recent study suggested that
differential activation of inflammatory signaling networks
distinguished lethal from sublethal infections. From com-
bined flow cytometry and gene expression analysis of
isolated cell subpopulations from infected mouse lungs
showed that neutrophil influx was largely responsible
for the predictive transcriptional signatures. Together
with these gene expression and flow data, automated ima-
ging analysis identified chemokine-driven proinflammatory
neutrophils, which might be activated by lethal viral loads.
In line with these data, attenuation, but not ablation, of the
neutrophil-driven response was shown to improve survival
without changing viral spread. These findings with a pos-
sible a roadmap for the systematic dissection of infection-
associated tissues support evidence for the primary contri-
bution of damaging innate inflammation to some forms of
influenza-induced lethality and provide. To more clearly
differentiate host protective from damaging immunity,
comprehensive data sets at both the organ and the cell
level are needed.
As described above, RSV is also an important human
respiratory pathogen against which there is no vaccine.
Systemic gene expression signatures have been examined
in lungs of mice infected with RSV (Pennings et al. 2011;
Janssen et al. 2007; Tripp et al. 2013). A robust tran-
scriptional response of interferon-associated and innate
immunity genes was observed at day 1 (pi) but was re-
duced by day 3 pi, and the peak lung transcriptional re-
sponse preceded the peak of viral replication. Host genes
that were expressed were diverse and involved in the IFN
response, inflammation, chemoattraction, and antigen
processing. In particular, cytokine genes such as IL-1β or-
chestrate the proinflammatory response while others in-
cluding intracellular reactive oxygen species (ROS) were
effectors of inflammation (Janssen et al. 2007; Tripp et al.
2013; Segovia et al. 2012).
Host innate immune responses in response to vaccin-
ation are relatively not well understood yet. The live atten-
uated yellow fever vaccine 17D (YF-17D) is considered
one of most effective vaccine with a 65-year history. YF-
17D was shown to activate human monocyte-derived DCs
by up-regulating CD80, CD86 markers and inflammatory
cytokines (IL-6, TNF-α), and chemokines (IP-10, MCP-1)
(Querec et al. 2006). Using CD11c+ DCs derived from
mutant mice, YF-17D was found to stimulate DCs via
multiple TLRs 2, 7, 8, and 9 to elicit the proinflamma-
tory cytokines IL-12p40, IL-6, and IFN-α. Mice with a
transfer of OT-I T cell receptor transgenic T cells and
inoculated with YF-Ova8 induced a mixed T helper cell
(Th)1/Th2 cytokine profile and CD8 T cells. Thus, effec-
tive vaccines may need to activate multiple innate immune
components.
Systems biology in humans for better understanding of
disease and vaccination
Systems biology in humans with respiratory viral infections
Systems biology is a newly advancing field that uses an
interdisciplinary approach aimed at understanding and pre-
dicting the properties of a living system through systematic
quantification of all its components and intensive mathem-
atical and computational modeling. Each component of the
system is measured using high-throughput ‘omic’ tech-
niques and in theory examined from the cellular level
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to the whole organism. Systems technologies include
transcriptomic (microarray gene expression), modern mass
spectrometry (proteomics, lipidomics, metabolomics),
genomics, and protein-DNA interaction (chromatin
immunoprecipitation).
A recent study (Mejias et al. 2013) reported whole
blood gene expression profiles of microarray data to as-
sess disease severity in infants (ages <6 months, 2 to 24
months) with respiratory syncytial virus infection in com-
parison with influenza and human rhinovirus (HRV),
attempting to identify biomarkers that can objectively
predict RSV disease severity. Despite the fact that influ-
enza, RSV, and HRV infect common respiratory tracts,
this study demonstrated that the degree of activation/
suppression of specific immune-related genes was mark-
edly different. Influenza stimulated a stronger activation
of interferon, inflammation, monocyte, and innate im-
mune response genes compared with RSV and rhinovirus.
Neutrophil-related genes were significantly overexpressed
in patients with RSV, followed by patients with rhinovirus,
and were at a lower level in patients with influenza. Inter-
estingly, RSV was associated with marked suppression of
genes involved in B cell, T cell, lymphoid lineage, and anti-
microbial responses. In contrast, this suppression was sig-
nificantly milder or absent in children with influenza and
rhinovirus.
The overexpression of interferon and innate immunity
genes was similar in children with moderate and severe
RSV but greater than that in children with mild RSV
disease. The overexpression of neutrophil, monocyte,
and innate immunity genes induced during the RSV
acute disease faded over time. However, T cell lymphoid
lineage and antimicrobial response genes were suppressed
during the acute phase and then recovered back to normal
levels. Remarkably, the suppression of B cell genes was
persistent when patients' samples were analyzed 1 month
after the acute infection. This low level of B cell genes
might explain partially the less protective antibody re-
sponses after acute RSV infection. This study also indi-
cates that RSV suppressed both the adaptive and innate
responses more severely in younger infants less than
6 months old. Children with severe RSV demonstrated
significantly greater underexpression of genes associated
with T cells, cytotoxic and NK cells, and plasma cells.
Influenza triggers a more robust immune response
than RSV, with greater induction of respiratory and sys-
temic cytokines (Garofalo et al. 2005; Gill et al. 2008;
Welliver et al. 2007). Antiviral responses against influ-
enza and RSV were shown to be correlated with the
interferon signature gene expression from peripheral
blood mononuclear cells isolated from patients with
acute influenza or RSV bronchiolitis (Ioannidis et al.
2012). This study provides evidence of the profound
systemic dysregulation of both the innate and adaptive
immune response induced by RSV infection in children
and supports systems biology of gene expression profiling
as a practical and powerful strategy to objectively stratify
children with viral infection such as RSV. Nonetheless,
these observations will require further analysis, as they
may have implications for RSV vaccine development.
Systems vaccinology
One potential application of systems biology is to predict
vaccine efficacy in humans. Molecular patterns or sig-
natures of genes in the blood after vaccination might
predict the later development of protective immune re-
sponses, representing a strategy to prospectively deter-
mine vaccine efficacy. Blood cells provide a snap-shot
of many lineages and differentiation states within the im-
mune system including the sites of vaccination. Micro-
array analyses using the Affymetrix Human Genome
U133 Plus 2.0 array of total PBMCs revealed a molecu-
lar signature comprised of genes that are involved in in-
nate sensing of viruses and antiviral immunity, in most
of the vaccines.
YF-17D is a live-attenuated yellow fever virus, one of
most effective successful human vaccines ever developed
(Querec et al. 2009; Gaucher et al. 2008) and would pro-
vide an excellent model for systems vaccinology study
in humans. YF-17D single vaccination induces antigen-
specific CD8+ T cells and neutralizing antibody responses
in humans that persist for several decades (Pulendran
2009; Pulendran et al. 2013). Recent studies (Querec et al.
2009; Gaucher et al. 2008) reported transcriptomic ana-
lysis of PBMCs isolated 3 to 7 day-post-vaccination of
healthy adults with YF-17D. In these studies, a pattern
of gene expression profile was revealed, which consists
of genes encoding proteins involved in antiviral sensing
and viral immunity, including the type I IFN pathway.
It seems to be that the YF-17D vaccine is mimicking an
acute viral infection.
Using computational analysis, signatures of gene ex-
pression in human PBMCs after vaccination appeared
to be correlated with the magnitude of the antigen-
specific CD8+ T cell and neutralizing antibody respon-
ses afterward (Querec et al. 2009). The functional
relevance of one of the genes within the predictive sig-
natures was speculated from machine-learning techniques
to validate the predictive capacity (ref 22). Eukaryotic initi-
ation factor-α kinase 4 (EIF2AK4) would be involved in
programming professional antigen presenting cells (DCs)
to stimulate CD8+ T cell responses (Querec et al. 2009). A
TNFRSF17 gene signature was predicted to be correlated
with neutralizing antibody responses. TNFRSF17 encodes
the receptor for the B-cell growth factor BLyS-BAFF
known to play a key role in the differentiation of plasma
cells (Vincent et al. 2013).
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The potential application of systems vaccinology in
humans was further extended by studies on immunity
to human influenza vaccines, the trivalent inactivated
seasonal influenza vaccine (TIV) (Nakaya et al. 2011;
Bucasas et al. 2011; Franco et al. 2013), and LAIV (FluMist)
(Nakaya et al. 2011). TIV is the most common flu shot
vaccine, which is a mixture of inactivated split H1N1,
H3N2, and influenza B vaccines. To determine whether
molecular signatures after YF-17D vaccination would
be similar to other vaccines such as influenza, a recent
study carried out a systems analysis of responses to
TIV and LAIV in young healthy adults during three
consecutive influenza seasons (Nakaya et al. 2011). The
group of people who received TIV showed higher anti-
body titers and more plasmablasts compared to the
group who received nasal spray of LAIV. As expected
from the fact that replicating LAIV infects mucosal tis-
sues of respiratory tracts, humans with a nasal spray of
LAIV showed a robust type I IFN antiviral transcrip-
tomic signatures. TIV-vaccinated humans also expressed
some gene encoding type I interferons and related pro-
teins as well as gene encoding proinflammatory mediators
(Nakaya et al. 2011). In this study, genes that are involved
in innate sensing of viruses and antiviral responses were
highly expressed within 1 to 3 days after vaccination of
humans (Nakaya et al. 2011). After 3 to 7 days of vaccin-
ation, the up-regulated genes (TNRSF17, XBP-1) were
found to be involved in the differentiation of plasmablasts,
which is likely to be correlated with the magnitude of the
later hemagglutin titers (Nakaya et al. 2011). Other studies
also demonstrated a plausible correlation between this
‘plasmablast signature’ and its capacity to predict antibody
titers (Obermoser et al. 2013; Furman et al. 2013; Tsang
et al. 2014).
Conclusions
In summary, recent advances in applying systems-level
approaches to virus, vaccines, cells, organs, animals, and
even to humans revealed extensive new information on
gene expression and protein components, thus showing
some promises in future. This new information extend
our understanding in the pathogen-host cell interactions,
host cellular responses, disease pathogenesis, host im-
mune responses, and eventually new therapeutics and
novel vaccine development. However, it should be remin-
ded that microarray data may fail to provide convincing
significance in our complex biological systems. In addi-
tion, the results of systems analysis need to be validated
by experiments generating functional data such as protein
techniques, gene perturbation, or deficient animal models.
Finally, systems biology requires multidisciplinary and
close collaborative experts including biologists, vaccino-
logists, immunologists, systems bioinformatics, computa-
tional specialists, and clinicians.
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